Evaxion Biotech A/S (NASDAQ:EVAX) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research report released on Friday morning, Benzinga reports. They currently have a $14.00 price target on the stock.

Evaxion Biotech A/S Trading Up 1.9 %

Shares of NASDAQ EVAX opened at $2.64 on Friday. The business’s 50 day moving average is $2.95 and its 200-day moving average is $3.18. Evaxion Biotech A/S has a 1-year low of $2.26 and a 1-year high of $13.61. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $3.02 million for the quarter, compared to analyst estimates of $0.19 million. Analysts expect that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Armistice Capital LLC lifted its stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 392,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Armistice Capital LLC owned 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.